Author

Zi-Rong Chen

Institution: National Cheng Kung University

Observed institutions: National Yang Ming Chiao Tung University, National Cheng Kung University

ORCID: 0000-0002-4777-6792

Observed ORCID: 0000-0002-4777-6792

OpenAlex ID: A5043280238

Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy

2022 · Chen-Han Chueh, Yi-Wen Tsai, et al. · PharmacoEconomics · 17

Acute resistance exercise combined with whole body vibration and blood flow restriction: Molecular and neurocognitive effects in late-middle-aged and older adults

2024 · Chia-Liang Tsai, Zi-Rong Chen, et al. · Experimental Gerontology · 11

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

2023 · Zi-Rong Chen, Chen-Han Chueh, et al. · Cost Effectiveness and Resource Allocation · 10

Works count: 3

Citation count: 38

H-index: 3

I10-index: 3